Stockrabit · Analysts
Questions across 3 calls

Steve Byrne

Bank of America

UPL Limited

UPL Limited CC-Dec24.pdf · 2025-01-31
Mike, your comments about the NPP in the slide deck really captured my attention. I was curious to hear your view on what would you rank as the primary drivers of the increased demand for your NPP products? Is it the regulatory path and registration of these NPP products? Is it just more streamlined? Is that a key driver? Is it the distribution channel that see these products as an attractive bolt -on. They can put them into their routine applications? Or is it at the grower level where these products like the biostimulants have a yield benefit? How would you rank those as driving the growth in these products?
And one more for you, and that is in the U.S. market, are you seeing any increased interest from either the wholesale or the retail distribution channel to be more interested in, say private label products or potentially more interested in something other than the primary branded products that they have contracts with. Is there increased interest in that? And is that an opportunity for you because you provide the certainty of supply that if they were to just go directly to active generic out of China, there may be less certainty on the supply, particularly with tariffs.
UPL Limited CC-Sep24.pdf · 2024-11-11
Mike, I was curious to hear your view on a potential change in international trade if the Red Wave in the US were to impose some meaningful tariffs on exports from China into the U.S. Anything in there that might be a potential benefit to you? The other on e I was curious to hear your view on is the ITC investigation in the U.S. on anticompetitive trading and contracts with crop chems, any involvement with your business on that? And anything I can glean from your outlook for that?
Ok, Thank you for that , and maybe a couple of outlook questions for you. One being in your - biologicals. You have some strong growth there. You commented on biostimulants, but what about anything in your pipeline you're particularly excited about in biologicals? Anything that you'd like to comment on there? And then the other one would be in Advanta Seeds, the European Union is certainly looking at more favourable regulatory scheme on using gene editing in seeds, is that a potential benefit to your seed business?
UPL Limited CC-Dec23.pdf · 2024-02-02
Mike, you made a comment about it's going to take a little bit longer to recover in the US and Brazil. I was curious whether you're referring to destocking? Or were you referring to price? I was also curious to hear your progress on your launch o f your brand of the Chlorantraniliprole product?
And Mike, if ‘I could squeeze one more in with you. What is it that makes it so challenging to monitor the channel inventory levels? Or do you think that you've made some adjustments in your own assessments to be able to monitor that better?